AstraZeneca anti-COVID vaccine, paused after adverse reaction to a participant



[ad_1]

Pharmaceutical AstraZeneca announced on Tuesday a global halt in clinical trials of its experimental vaccine against COVID-19 after the appearance of an unexplained disease in a participant.

“In the global randomized clinical trials of the coronavirus vaccine at the University of Oxford, our normal evaluation process was started and we voluntarily stopped the vaccines to allow for a safety assessment by an independent committee.”Said the company, an industrial partner of the British university, in a statement, according to Agerpres.

A company spokesperson described the breakdown as “a routine action that should be carried out whenever there is a potentially unexplained illness in one of the studies, while it is being investigated, ensuring that we maintain the integrity of the studies’, broadcasts Statnews.

According to the New York Times, a volunteer from the United Kingdom was diagnosed transverse myelitis (an inflammation of the spine), which can lead to spinal cord injury and is caused by viral infections.

However, the cause of this condition has not been confirmed, and independent research aims to investigate whether there is any connection to the Covid vaccine, writes the BBC.

The vaccine is currently in the third phase of clinical trials.

300 million dose contract with EC

The European Commission announced at the end of August the signing, on behalf of the EU member states, of a contract with the British-Swedish pharmaceutical company AstraZeneca for the purchase of 300 million doses of the COVID-19 vaccine, which is currently being sold. Its testing. the community executive.

The contract comes after the signing of a pre-purchase agreement in August. This is the first contract signed by the EU to buy a possible vaccine against the new coronavirus. The contract also provides for the option to purchase an additional 100 million doses.

The signed document also states that the EU member states “I can compensate the manufacturer (AstraZeneca) under certain conditions” to compensate ‘‘high risk’ ‘ of the vaccine development process.

In Instagram ProTV News Find the images of the moment in the world!

CLICK HERE to install the FREE ProTV News app for Android phones and iPhone!



[ad_2]